Can You Reverse Diabetes? Remission, Causes, and What Works

Can you reverse diabetes?

Short answer: type 2 diabetes can go into remission, and prediabetes can return to normal — but the window is widest early, and it narrows every year you wait. Type 1 is a different disease with a different answer. In two decades of practicing medicine, the single most expensive mistake I watch people make with blood sugar is treating an early abnormal number as something to "keep an eye on." That is the exact moment the odds are best, and it is the moment most people do nothing.

The honest word is remission, not cure

Remission of type 2 diabetes has a formal definition: an A1c under 6.5 percent sustained for at least three months without any glucose-lowering medication. That is a real, meaningful, documentable achievement. It is not a cure. Somewhere between a third and half of people who reach remission eventually relapse, and after bariatric surgery diabetes returns in more than half within about ten years. I would rather tell you that up front than sell you a word I cannot back. Remission is a state you get into and then have to keep, which is a different project than a one-time fix.

What actually causes diabetes

This matters more than most people realize, because the cause determines whether reversal is even on the table. Every form of diabetes ends at the same place — not enough insulin action — but they arrive by very different roads.

Type 1 is autoimmune. Your own immune system destroys the insulin-producing beta cells in the pancreas, and the result is an absolute insulin deficiency. Islet autoantibodies show up in the blood years before symptoms do. Genetics load the gun — the HLA region accounts for something like 40 to 50 percent of genetic risk, with dozens of other loci contributing — but they do not fire it alone: identical twin concordance is only around 65 percent, and roughly 90 percent of newly diagnosed patients have no affected family member at all. Enteroviral infection has the strongest evidence among environmental triggers, with gut microbiome, vitamin D status, and body weight also implicated.

Type 2 is two problems stacked. First, insulin resistance in muscle, liver, and fat tissue — which can be present for a decade or more before anyone gives you a diagnosis. Second, beta cells that cannot keep compensating, and whose secretory capacity declines progressively over time. That decade of silent resistance is the reason early intervention works and late intervention struggles: you are trying to save beta cell capacity that has not been spent yet. The modifiable drivers are the familiar list, with adiposity carrying the strongest evidence: excess weight, physical inactivity, sedentary time, a diet heavy in processed meat and sugar-sweetened beverages and light on whole grains, and smoking. The non-modifiable ones are age, family history, ancestry, prior gestational diabetes, and PCOS. Worth knowing: BMI is a stronger predictor than genetic risk scores, and about 10 percent of people with type 2 are not overweight at all. Sleep deprivation, sleep apnea, and certain medications including glucocorticoids belong on the list too, and they get missed constantly.

Gestational diabetes happens when placental hormones drive insulin resistance up by 40 to 50 percent and the beta cells cannot mount the matching increase in output. It is often the first visible sign of a beta cell problem that was already there, which is precisely why it is such a strong predictor of type 2 later.

And then there are the ones that get mislabeled. Monogenic diabetes such as MODY, disease of the pancreas itself, endocrine disorders like Cushing syndrome or acromegaly, and drug-induced diabetes are all real and all routinely filed under "type 2" by default. If someone is thin, young, has an unusual family pattern, or is not responding the way the diagnosis predicts, that assumption deserves to be tested rather than inherited.

Prediabetes: the best odds you will ever have

If you have been told you have prediabetes, you have been handed the most valuable information in this whole page. The Diabetes Prevention Program cut new cases of type 2 by 58 percent over three years with structured lifestyle change, and the benefit held up remarkably long — 34 percent at ten years, 27 percent at fifteen, 24 percent at twenty-one. Forty percent of the intensive lifestyle group returned to normal glucose regulation at three years, roughly double what medication or placebo achieved. The two anchors of that program were sustained weight loss and at least 150 minutes a week of moderate activity.

Two details worth carrying with you. Reversion depends heavily on subtype: roughly 31 percent revert when only fasting glucose or only A1c is abnormal, but only about 8 percent when both are — so the combination is the alarm, not the shrug. And reaching normal glucose even once is protective in its own right, associated with a 56 percent lower ten-year incidence of diabetes and less microvascular disease down the line. Newer data also suggest remission can happen without weight loss, through improved insulin sensitivity alone. That is real, and it is also not the way to bet if weight is part of your picture.

Type 2 remission: what the evidence actually shows

Weight loss is the engine. The relationship is a clean dose-response: every one percent drop in body weight raises the probability of remission by roughly two percent, and losing more than ten percent of your baseline weight in the first year after diagnosis is associated with a 70 percent higher chance of remission at five years. In the DiRECT trial, 70 percent of people who lost 15 kilograms or more were in remission at two years, compared with 5 percent of those who lost less than 5. That is not a subtle gradient. It is the whole story.

Duration matters as much as effort. Remission works best in recently diagnosed people because there is more beta cell reserve left to rescue. Metabolic surgery produces the highest and most durable rates — in the pooled ARMMS-T2D analysis, about 51 percent at one year and 18 percent at seven years, versus 0.5 percent and 6 percent with medical and lifestyle management — but note that even surgery’s numbers fall over time. Nothing here is permanent. Everything here is worth doing.

Type 1: not reversible, but the ground is moving

I will be direct, because people with type 1 get sold hope constantly. No approved therapy halts or reverses established autoimmune beta cell destruction. Insulin remains the standard of care and it does not cure the disease. What has changed: teplizumab, approved in 2022, can delay progression from early-stage to clinical type 1 by roughly two years in high-risk individuals — delay, not reversal. Stem cell–derived beta cell replacement, encapsulation devices, gene editing, and combination immunotherapies have produced instances of insulin independence in early trials, but most still require immunosuppression and none has durable long-term efficacy yet. That is genuinely exciting research. It is not a treatment you can act on today, and anyone telling you otherwise is not being straight with you.

Why remission is worth chasing even if it does not last

This is the part that convinced me to take remission seriously as a goal rather than a talking point. In the Look AHEAD analysis, any evidence of remission during follow-up was associated with a 40 percent lower rate of cardiovascular events and a 33 percent lower rate of high-risk chronic kidney disease. A UK cohort of roughly 60,000 people found substantially lower microvascular and macrovascular complication risk with sustained low A1c — and even transient remission was associated with lower mortality. A real-world Hong Kong cohort found remission associated with 31 percent lower all-cause mortality. On the prediabetes side, thirty-year follow-up from Da Qing showed lower cardiovascular death and fewer microvascular complications in those who reverted to normal glucose.

The honest caveat: most of this is observational or post-hoc, so remission is best understood as a powerful prognostic marker and a reasonable target rather than proof of cause and effect. Much of the benefit appears to run through the things that produce remission in the first place — weight, glucose, blood pressure, lipids — and some microvascular associations fade once you adjust for average A1c over time. Translation: the cumulative glucose exposure across your life is what your blood vessels are actually counting. Remission is how you lower that number.

Why this needs a consultation and not a search bar

Everything above is population data. None of it tells you which situation you are in, and that is the only question that matters. A visit answers things a website structurally cannot: which type of diabetes you actually have and whether the label you were given is correct; how much beta cell function you have left, which sets what is realistically achievable; whether something else is driving this entirely — thyroid, cortisol, sleep apnea, a medication you were handed for an unrelated problem; whether your kidneys, liver, and lipids are already carrying damage; and where your weight, hormones, and metabolic markers actually sit rather than where you assume they do.

Then we build the plan around your numbers. That may mean nutrition and activity structured to a real target rather than a vague intention. It may mean medication, including the GLP-1 class where appropriate. It may mean referral for surgical evaluation if that is genuinely the highest-yield path for you. It may mean fixing the thing nobody has looked at yet. Whatever it is, it is individualized and it comes through our office — because a treatment plan built from an article is a plan built for a person who is not you.

And I want to be blunt about timing. Beta cell function is the resource you are spending. The evidence is unambiguous that early and substantial intervention beats late and gradual, by a wide margin. If you have a fasting glucose or an A1c that came back "a little high," that is not a number to monitor. That is the appointment.

Measure, don’t guess

One blood draw tells us whether you are looking at prediabetes, established type 2, something autoimmune, or something that was never type 2 to begin with. It also tells us how much time you have and how hard to push. Related reading: fatty liver (MASLD) and how to reverse it, GLP-1 benefits beyond weight loss, and the six daily habits that carry the most weight.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

References

This page covers general health information and is not a substitute for individual medical advice. Never start, stop, or change a diabetes medication on your own — talk with your physician about your own situation.

Diabetes Care, 2026 — ADA Standards of Care: diagnosis and classification of diabetes.
Diabetes Care, 2026 — ADA Standards of Care: prevention or delay of diabetes and associated comorbidities.
Diabetes Care, 2026 — ADA Standards of Care: obesity and weight management in diabetes.
Diabetes Care, 2025 — type 2 diabetes remission: systematic review and meta-analysis of nonsurgical randomized trials.
The Lancet, 2022 — obesity management as a primary treatment goal for type 2 diabetes.
JAMA, 2024 — long-term outcomes of medical management versus bariatric surgery in type 2 diabetes.
Cochrane Database of Systematic Reviews, 2026 — metabolic and bariatric surgery in adults with obesity and diabetes: network meta-analysis.
Diabetologia, 2024 — impact of remission from type 2 diabetes on long-term health outcomes (Look AHEAD).
PLoS One, 2023 — type 2 diabetes remission trajectories and variation in complication risk.
PLoS Medicine, 2024 — one-year weight change after diagnosis and long-term remission in real-world settings.
Diabetes Care, 2026 — 15 percent weight loss within two years of diagnosis and complication risk.
The Lancet Diabetes & Endocrinology, 2026 — prediabetes remission and cardiovascular morbidity and mortality (DPPOS and Da Qing).
The Lancet Diabetes & Endocrinology, 2023 — mechanisms of weight loss–induced remission in prediabetes (PLIS).
Nature Medicine, 2025 — prevention of type 2 diabetes through prediabetes remission without weight loss.
JAMA, 2023 — diagnosis and management of prediabetes.
American Journal of Preventive Medicine, 2022 — interventions for reversing prediabetes: systematic review and meta-analysis.
Scientific Reports, 2021 — heterogeneity of reversion to normoglycemia by prediabetes type.
Diabetes Care, 2019 — regression from prediabetes to normal glucose regulation and microvascular disease (DPPOS).
JAMA, 2026 — type 1 diabetes: review.
The Lancet, 2023 — type 1 diabetes.
Diabetes Technology & Therapeutics, 2025 — a cure for type 1 diabetes: are we there yet?
JAMA, 2025 — diagnosis and treatment of type 2 diabetes in adults.
PLoS One, 2018 — risk factors for type 2 diabetes: umbrella review of meta-analyses.
Diabetes, 2025 — what is gestational diabetes, really?
Nature Reviews Endocrinology, 2016 — common and rare forms of diabetes: toward a continuum of subtypes.